Scott Gottlieb

[American Enterprise Institute @AEI]

AEI Senior Fellow @ScottGottliebMD joins CNBC’s Squawk Box to discuss the FDA’s new efforts to improve competitiveness with China, new leadership, and where the agency is headed.

[Squawk Box @SquawkCNBC]

The FDA wants to accelerate the early stages of clinical trials and get action the country is losing to China and Australia back on U.S. shores. Former FDA Commissioner @ScottGottliebMD weighs in. https://t.co/nzXTC7krPL

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

👏👏 US has an inherent advantage in conducting proof-of-concept studies, because good medical care, to support patients receiving complex therapies, is key and US does that best

But the time and cost advantage can’t tilt so heavily against US-based trials or we’ll lose our edge

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

🧵 Important from FDA today -- a new, broad initiative to improve clinical trial efficiency with aim of maintaining 🇺🇸 biomedical edge over 🇨🇳. Reform entails a long series of small changes that, taken together, tilt the playing field back in US favor. This is a key start...

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

My editorial in JAMA Health Forum on restoring FDA's strength. 'The periods of greatest credibility--and greatest administrative and legislative success--have coincided with strong career leadership in the centers paired with effective commissioners' @AEI
https://t.co/BgPHyOSoqd

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

I'm honored to be joining the governing council of the National Academy of Medicine, along with four distinguished colleagues and the Academy's new Home Secretary, Dr. Robert L. Phillips.

https://t.co/4gf708RNtY

[Squawk Box @SquawkCNBC]

.@ScottGottliebMD breaks down the details of the Ebola outbreak & risks to the population:
https://t.co/H2KzsSlmtp

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

My segment today on @SquawkCNBC on @CNBC on FDA issues, vaping policy, and updates on hantavirus. @AEI #Vaping #FDA #Hantavirus

https://t.co/qVXwsCtAcR

[Squawk Box @SquawkCNBC]

What's the risk of a wider hantavirus outbreak? @ScottGottliebMD breaks it down: https://t.co/W32jtAw6uL

[Face The Nation @FaceTheNation]

WATCH: Former FDA commissioner Dr. Scott Gottlieb’s conversation with @margbrennan on “Face the Nation.”

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

New study has strengthened link between infectious mono and Multiple Sclerosis. By analyzing 2 decades of health records, researchers found people who contracted mono as teenagers or adults were 3x more likely to develop MS later vs those who didn’t

https://t.co/6DLZMEWyU6

[American Enterprise Institute @AEI]

AEI’s @ScottGottliebMD joins CNBC’s Squawk Box to discuss why the FDA’s new rare disease framework is an encouraging first step and how FDA can build on the guidance to create a path for the clinical development of new therapies.

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

My @CNBC segment on how President Trump's drug pricing deals will achieve many of the initial aims set out by tariff proposals, with respect to reshoring drug manufacturing, and how the biggest consumer impact in terms of lower drug costs is set to unfold
https://t.co/q2Q9gQB94F

[Squawk Box @SquawkCNBC]

Former FDA Commissioner @ScottGottliebMD explains why tariffs are an inefficient tool to reshore drug manufacturing: https://t.co/Si9DJK7Gha

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

These proposed reforms to pre-clinical drug development and to smoothing the transition to first-in-human studies could be the most consequential steps toward leveling the playing field with China.

https://t.co/oVY6N3xo9Y

[Squawk Box @SquawkCNBC]

$NVO is suing $HIMS over copycat weight loss drugs. @ScottGottliebMD breaks down what it means for the industry:
https://t.co/zvgiFFpBHk

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

My Op Ed in Today's @PostOpinions "The long-lasting effects of viruses — and the anti-vaccine movement. For some people, a viral infection can have devastating long-term effects."

https://t.co/lbPSaBikxv

[Face The Nation @FaceTheNation]

FULL INTERVIEW: As the CDC vaccine panel voted last week to stop recommending the birth dose of the Hepatitis B vaccine, former FDA Commissioner @ScottGottliebMD, who now serves on the boards of Pfizer and United Healthcare, told @margbrennan that the birth dose in addition to two subsequent doses is "almost 99% effective at preventing that chronic infection." https://t.co/ikMp2KDXsG

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

My op ed in today's @washingtonpost - 'With China undermining U.S. biotech, here’s how the FDA can counter: Lower the costs of development for American scientists, too.' @AEI

https://t.co/ksk4SWTFuf

[Face The Nation @FaceTheNation]

The U.S. is “not at risk” from the current mpox outbreak right now, @ScottGottliebMD says. But a new variant “that appears to spread a little more easily” is raising concerns about further spread because it has “potentially more pandemic potential,” he adds. Here’s what you need to know: